И его применение при заболеваниях легких

9. 
Baughman R. P., Stein E., MacGee J. et al. Changes in fatty acids in phos
pholipids of the bronchoalveolar fluid in bacterial pneumonia and in
adult respiratory distress syndrome. Clin. Chem. 1984; 30: 521—525. 
10. Baughman R. P., Sternberg R., Hull W. et al. Decreased surfactant protein A in
patients with bacterial pneumonia. Am. Rev. Respir. Dis. 1987; 147: 653—658. 
11. Gunther A., Siebert C., Schmidt R. et al. Surfactant alterations in severe
pneumonia, ARDS and cardiogenic lung edema. Am. J. Resp. Crit. Care
Med. 1996; 153: 176—184. 
12. Lewis J., Veldhuizen R. The role of surfactant in pneumonia and sepsis.
Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 55—57. 
13. von Bredow C., Birrer P., Griese M. Surfactant protein A and other bron
choalveolar lavage fluid proteins are altered in cystic fibrosis. Eur.
Respir. J. 2001; 17: 716—724. 
14. Griese M., Birrer P., Demirsoy A. Pulmonary surfactant in cystic fibrosis.
Eur. Respir. J. 1997; 10: 1983—1997. 
15. McCormack F. X., King T. E., Voelker D. R. et al. Idiopathic pulmonary
fibrosis. Abnormalities in the bronchoalveolar lavage content of surfac
tant protein A. Am. Rev. Respir. Dis. 1991; 144: 160—169. 
16. Robinson P. S., Watters L. C., King T. E. et al. Idiopathic pulmonary fibro
sis. Abnormalities in the bronchoalveolar lavage fluid phospholipids.
Am. Rev. Respir. Dis. 1988; 137: 585—592. 
17. Oyarzun M. J., Stevens P., Clemens J. A. Effect of lung collapse on alveo
lar surfactant in rabbits subjected to unilateral pneumothorax. Exp.
Lung Res. 1989; 15: 90—96. 
18. Hallman M., Maasita P., Kivisaari L. et al. Changes in surfactant in bron
choalveolar lavage fluid after hemithorax irradiation in patients with
mesothelioma. Am. Rev. Respir. Dis. 1990; 141: 998—1007. 
19. Ackerman S. J., Kwatia M. A., Doyle C. B. et al. Hydrolysis of surfactant
phospholipids catalyzed by phospholipase A2 and eosinophil lysophos
pholipases causes surfactant dysfunction: a mechanism for small airway
closure in asthma. Chest 2003; 123: 355—361. 
20. Cheng G., Ueda T., Numao T. et al. Increased levels of surfactant protein
A and D in bronchoalveolar lavage fluids in patients with bronchial
asthma. Eur. Respir. J. 2000; 16: 831—835. 
21. Haczku A., Atochina E. N., Tomer Y. et al. The late asthmatic response is
linked with increased surface tension and reduced surfactant protein B
in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283: 755—760. 
22. Hohlfeld J., Ahlf K., EnhorningG. et al. Dysfunction of pulmonary sur
factant in asthmatics after segmental allergen challenge. Am. J. Respir.
Crit. Care Med. 1999; 159: 1803—1809. 
23. Hohlfeld J. M., Schmiedl F., Erpenbeck V. J. et al. Eosiniphil cationic pro
tein (ECP) alters pulmonary structure and function in asthma. J.
Allergy Clin. Immunol. 2004; 113: 496—502. 
24. Wang J. Y., Shieh C. C., Yu C. K. et al. Allergeninduced bronchial inflam
mation is associated with decreased levels of surfactant proteins A and
D in a murine model of asthma. Clin. Exp. Allergy 2001; 31: 652—662. 
25. Wright S. M., Hockey P. M., Enborning G. et al. Altered airway surfactant
phospholipids composition and reduced lung function in asthma. J.
Appl. Physiol. 2000; 89: 1283—1292. 
26. Devendra G. Spragg R. G. Lung surfactant in subacute pulmonary dis
ease. Respiratory Res. 2002; 3: 19—30. 
27. Günther A. et al. Surfactant abnormalities in idiopathic pulmonary
fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J.
1999; 14: 565—576. 
28. Ерохин В. В. Морфофункциональное состояние клеток легких при
туберкулезном воспалении. В кн.: Ерохин В. В., Романова Л. К.
(ред.) Клеточная биология легких в норме и при патологии. Руко
водство для врачей. М.: Медицина; 2000. 496—518. 
29. Rosenberg O., Bautin A., Osovskich V. et al. Surfactant therapy for acute
and chronic lung diseases. Appl. Cardiopulm. Pathophysiol. 2004; 13
(1): 78—78. 
30. Fujiwara T., Maeta H., Chida S. et al. Artificial surfactant therapy in
hyaline membrane disease. Lancet 1980; 1: 55—59. 
31. Lachmann B. Surfactant replacement in acute respiratory failure:
Animal studies and first clinical trials. In.: Lachmann B. (ed.)
Surfactant replacement тherapy. N. Y.: SpringerVerlag; 1987. 212—220. 
32. Spragg R. G. Current status of surfactant treatment of ARDS/ALI.
Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 88—90. 
33. Gregory T. J., Gadek J. E., Weiland J. E. et al. Survanta supplementation
in patients with acute respiratory distress syndrome (ARDS). Am. J.
Resp. Crit. Care Med. 1994; 49: 125—131. 
34. Rosenberg O. A., Bautin A. E., Osovskich V. V. et al. When to start sur
factant therapy (STtherapy) of acute lung injury? Eur. Respir. J. 2001;
18 (Suppl. 38): 153, 7s. 
35. Anzueto A., Baughman R., Guntupalli K. K. et al. Aerosolized surfactant
in adults with septicinduced acute respiratory distress syndrome. N.
Eng l. J. Med. 1996; 334: 1417—1421. 
36. Bonсˆuk=Dayanikli P., Taeusch W. H. Essential and nonessential con
stituents of exogenous surfactants. In: Robertson, B. Taeusch, H. W.
(eds.) Surfactant therapy for lung disease. Lung biology in health and
disease. 84. N. Y.; 1995: Marcel Dekker, Inc. 217—238. 
37. Günther A., Ruppert C., Schmidt R. et al. Surfactant alteration and
replacement in acute respiratory distress syndrome. Respir. Res. 2001;
2 (6): 353—364. 
38. Sanders R. L. The composition of pulmonary surfactant. In: Farrell P. M.
(ed.) Lung development: вiological and сlinical рerspectives. N. Y.:
Academic Press; 1982. 1. 193—210. 
39. Possmayer F. A proposed nomenclature for pulmonary surfactantasso
ciated proteins. Am. Rev. Respir. Dis. 1988; 138: 990—998. 
40. Persson A., Chang D., Rust D. et al. Purification and biochemical char
acterization of CP4 (SPD), a collagenous surfactantassociated pro
tein. Biochemistry 1989; 28: 6361—6367. 
41. Weaver T. E., Whitsett J. A. Function and regulation of expression of
pulmonary surfactantassociated proteins. Biochem. J. 1991; 273:
249—264. 
42. Goerke J., Clements J. A. Alveolar surface tension and lung surfactant. In:
Handbook of рhysiology. The Respiratory system. Mechanics of вreath
ing. 3 Am. Phisiol. Soc. Bethesda; 1986. Sect. 3. P I. 247—263. 
43. Schurch S., Bachofen H. Biophysical aspects in the design of a therapeu
tic surfactant. In: Rodertson B., Taeush H. W., (eds.) Surfactant thera
py for lung disease. Lung biology in health and disease. 84. N. Y.: Marcel
Dekker Inc; 1995. 3—26. 
44. Horie T., Hildebrandt J. Dynamic compliance, limit cycles and static
equilibria of excised cat lung. J. Appl. Physiol. 1971; 31: 423—428. 
45. Mead J., Collier C. Relation of volume history of lungs to respiratory
mechanics in anesthetized dogs. J. Appl. Physiol. 1959; 14: 669—675. 
46. Rosenberg O., Seiliev A., Zhuikov. Lung Surfactant: Correlation beween
biophysial charactrisic, composition, and therapeutic effiacy. In:
Gregory Gregoriadis, (ed.) Liposome тechnology. Taylor and Francis;
2006. 3ed, 3, сh. 17. 317—345. 
47. Bachofen H. et al. Relations among alveolar surface tension, surface
area, volume and recoil pressure. J. Appl. Physiol. 1987; 62: 18781891. 
48. Schürch S., Goerke J., Clements J. A. Direct determination of volume
and timedependence of alveolar surface tension in excised lungs. Proc.
Natl. Acad. Sci. USА 1978; 75: 3417—3420. 
49. Bachofen H. et al. Experimental hydrostatic pulmonary edema in rabbit
lungs. Morphology. Am. Rev. Respir. Dis. 1993; 147: 989—996. 
50. Bachofen H., Schürch, S., Weibel I. R. Experimental hydrostatic pul
monary edema in rabbit lungs. Barrier lesions. Am. Rev. Respir. Dis.
1993; 147: 997—1006. 
51. LaForce F. M., Kelley W. J., Huber J. L. Inactivation of staphylococci by
alveolar macrophages with preliminary observations on the importance
of alveolar lining material, Am. Rev. Respir. Dis. 1973; 108: 783—789. 
52. Wollmer P., Jonson B., Lachmann B. Evaluation of lung permeability. In:
Robertson B., Taeusch, H. W., (eds.) Surfactant therapy for lung dis
ease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.;
1995; 84. 199—215. 
53. Hohlfeld J., Fabel H., Hamm H. The role of pulmonary surfactant in
obstructive airway disease. Eur. Respir. J. 1997; 10: 482—491. 
54. Hohlfeld J. M. The role of pulmonary surfactant in asthma. Major com
ponents of surfactant (functions). Respir. Res. 2002; 3: 4—12. 
55. Bates S. R., Ibach P. B, Fisher A. B, Phospholipids coisolated with rat sur
factant protein C account for the apparent proteinenhanced uptake of lipo
somes into lung granular pneumocytes. Exp. Lung Res. 1989; 15: 695—708. 
56. Goerke J. Pulmonary surfactant: functions and molecular composition.
Biochim. Biophys. Acta 1998; 1408: 79—89. 
57. Cocksgutt A., Absolom D., Possmayer F. The role of palmitic acid in pul
monary surfactant: enhancement of surface activity and prevention of inhi
bition by blood proteins. Biochim. Biophys. Acta 1991; 1085: 248—256. 
58. Holm B. A., Venkitaraman A. R., Enchorning G. et al. Biophysical inhibition
of synthetic lung surfactants. Chem. Phys. Lipids 1990; 52: 243—250. 
59. Longo M. L., Bisango A. M., Zasadzinski J. et al. A function of lung sur
factant protein SPB. Science 1993; 261: 453—456. 
60. Tanaka, Y., Takei T., Aiba T. et al. Development of synthetic lung surfac
tants. J. Lipid Res. 1986; 27: 475—485. 
61. Orgeig S., Daniels C. B. The roles of cholesterol in pulmonary surfactant:
insights from comparative and evolutionary studies. Comp. Biochem.
Physiol. A Mol. Integr. Physiol. 2001; 129: 75—89. 
62. Bunt J. E. H. Surfactant therapy stimulates endogenous surfactant syn
thesis in premature infants. Crit. Care Med. 2000; 28: 3383. 
63. Ikegami M. SPB protects lung from inflammation. Appl. Cardiopulm.
Pathophysiol. 2004; 13 (1): 45—47. 
64. Miles P. R., Bowman L., Rao K. M. et al. Pulmonary surfactant inhibits
LPSinduced nitric oxide production by alveolar macrophages. Am. J.
Physiol. 1999; 276 (1P. 1): 186—196. 
65. van Iwaarden J. F., Claassen E., Jeurissen S. H. et al. Alveolar
macrophages, surfactant lipids, and surfactant protein B regulate the
induction of immune responses via the airways. Am. J. Respir. Cell Mol.
Biol. 2001; 24 (4): 452—458. 
66. Floros J., Phelps D. S., Pison U. et al. Pulmonary surfactantupdate on
function, molecular biology and clinical implications. Cur. Respiratory
Med. Rev. 2005; 1 (1): 77—84 
О Б Щ А Я Р Е А Н И М А Т О Л О Г И Я , 2 0 0 7 , I I I ; 1
75
О б з о р ы

67. Crouch E., Wright. J. R. Surfactant proteins A and D and pulmonary host
defense. Ann. Rev. Physiol. 2001; 63: 521—534. 
68. Phelps D. S. Surfactant regulation of host defense function in the lung:
a question of balance. Pediatr. Pathol. Mol. Med. 2001; 20: 269—274. 
69. Erpenbeck V. J., Malherbe D. C., Sommer S. et al. Surfactant protein D
regulates phagocytosis of Grass pollenderived starch granules by alveo
lar macrophages. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 31—32. 
70. Hawgood S. The hydrophilic surfactant protein SPA: Molecular biolo
gy, structure and function. In: Robertson B., Van Golde L. M. G.,
Batenburg J. J., (eds.) Pulmonary surfactant: From molecular biology
to clinical practice. Amsterdam: Elsevier; 1992. 33—54. 
71. Wright J. R. Immunomodulatory functions of surfactant. Physiol Rev.
1997; 77: 931—942. 
72. Wright J. R. Surfactant: A pulmonary link between innate and adaptive
immunity. Appl. Cardiopulm. Pathophysiol. 2004; 13: 104—105. 
73. Clark H., Palaniyar N., Strong P. et al. Surfactant protein reduces alveo
lar macrophage apoptosis in vivo. J. Immunol. 2002; 169 (6): 2892—2899. 
74. Clark H. W., Palaniyar N., Hawgood S. et al. A recombinant fragment of
human surfactant protein D reduces alveolar macrophage apoptosis and
proinflammatory cytokones in mice developing pulmonary emphyse
ma. Ann. N. Y. Acad. Sci. 2003; 1010: 113—116. 
75. Kaplan J. H., Casey J. A., Savani R. C. et al. Differential response of col
lectin deficient mouse models to bleomycin induced lung injury. Appl.
Cardiopulm. Pathophysiol. 2004; 13 (1): 51—52. 
76. Lewis J., Veldhuizen R. The role of surfactant in the pathophysiology of
acute lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 53—55. 
77. Clark J. C., Wert S. E., Bachurski C. J. et al. Targeted disruption of the sur
factant protein B gene disrupts surfactant homeostasis, causing respira
tory failure in newborn mice. Proc. Natl. Acad. Sci. USA 1995; 92 (17):
7794—7798. 
78. Nogee L. M., Garnier G., Dietz H. C. et al. A mutation in the surfactant
protein B gene responsible for fatal neonatal respiratory disease in mul
tiple kindreds. J. Clin. Invest. 1994; 93 (4): 1860—1863. 
79. Melton K. R., Nesslein L. L., Ikegami M. et al. SPB deficiency causes res
piratory failure in adult mice. Am. J. Physiol. 2003; 285: 543—549. 
80. Cochrane C. G. A critical examination of the role of SPB in alveolar
expansion, Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 27—29. 
81. Cruz A., Vazquez L., Bernardinjo J. et al. Analysis by scanning force
microscopy of the micro and nanostructure of LangmuirBlodgett pul
monary surfactant films. Appl. Cardiopulm. Pathophysiol. 2004; 13: 30—31. 
82. Cruz A. et al. Effect of pulmonary surfactant protein SPB on the micro
and nanostructure of phospholipids films. Biophys. J. 2004; 86: 308—310. 
83. Na Nkorn P., Flach C. R., Mendelsohn R. et al. The influence of truncat
ed surfactantprotein C (SPC17) on the surface properties of lipid
monolayers at the airwater interface. Appl. Cardiopulm. Pathophysiol.
2004; 13 (1): 62—63. 
84. Weaver T. E., Conkright J. J. Function of surfactant proteins B and C.
Annu. Rev. Physiol. 2001; 63: 555—578. 
85. Cotton R. B., Olsson T. Lung mechanics in respiratory distress syndrome.
In: Robertson B., Taeusch H. W. (eds.) Surfactant therapy for lung dis
ease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.;
1995; 84. 121—150. 
86. Floros J., Veletza V., Kotikalapudi P. et al. Dinucleotide repeats in the
human surfactant protein B gene and respiratory distress syndrome.
Biochem. J. 1995; 305: 583—590. 
87. Nogee L. M., deMello D. E., Dehner L. P. et al. Deficiency of pulmonary surfac
tant protein B in alveolar proteinosis. N. Engl. J. Med. 1993; 328: 406—410. 
88. Рейниш М. С., Розенберг О. А. Быстрый метод определения фосфо
липидов в амниотической жидкости. Лаб. дело 1978; (2): 98—100. 
89. Bernard G. R. et al. The AmericanEuropean consensus conference on
ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial
coordination. Am. J. Respir. Crit. Care Med. 1994; 149: 818—821. 
90. Gregory T. J., Longmore W. J., Moxley M. A. et al. Surfactant chemical
composition and biophysical activity in acute respiratory distress syn
drome. J. Clin. Invest. 1991; 88: 1976—1981. 
91. Hallman M., Spragg R., Harrell J. H. et al. Evidence of lung surfactant
abnormality in respiratory failure. Study of bronchoalveolar lavage
phospholipids, surface activity, phospholipase activity and plasma
myoinositol. J. Clin. Invest. 1982; 70: 673—683. 
92. Pison U., Seeger W., Buchhorn R. et al. Surfactant abnormalities in
patients with respiratory failure after multiple trauma. Am. Rev. Respir.
Dis. 1989; 140: 1033—1039. 
93. Green K. E., Wright J. R., Steinberg K. R. et al. Serial changes in surfac
tantassociated proteins in lung and serum before and after onset of
ARDS. Am. J. Resp. Crit. Care Med. 1999; 160: 843—1850. 
94. Lewis J. F., Veldhuizen R., Possmayer F. et al. Altered alveolar surfactant
is an early marker of acute lung injury in septic adult sheep. Am. J. Resp.
Crit. Care Med. 1994; 150 (1): 123—130. 
95. Veldhuizen R., McCaig L. A., Akino T. et al. Pulmonary surfactant sub
fractions in patients with the acute respiratory distress syndrome. Am.
J. Resp. Crit. Care Med. 1995; 152: 1867—1871. 
96. Cockshutt A. M., Weitz J., Possmayer F. Pulmonary surfactantassociated
protein A enhances the surface activity of lipid extract surfactant and
reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29:
8424—8429. 
97. Fuchimukai T., Fujiwara T., Takahashi A. Artificial pulmonary surfactant
inhibition by proteins. J. Appl. Physiol. 1987; 62: 429—437. 
98. Seeger W., Stohr G., Wolf H. R. Alteration of surfactant function due to
protein leakage: special interaction with fibrin monomer. J. Appl.
Physiol. 1985; 58: 326—338. 
99. Holm B. A., Notter R. H. Effects of hemoglobin and cell membrane
lipids on pulmonary surfactant activity. J. Appl. Physiol. 1987; 63:
1434—1442. 
100. Seeger W., Thede C., Gunter A. et al. Surface properties and sensitivity
to proteininhibition of a recombinant apoprotein Cbased phospho
lipids mixture in vitrocomparison to natural surfactant. Biochim.
Biophys. Acta 1991; 1081: 45—52. 
101. Seeger W., Gunther A., Thede C. Differential sensitivity to fibrinogen
inhibition of SPC vs. SPBbased surfactants. Am. J. Physiol. 1992;
262: 286—291. 
102. Venkitaraman A. R., Gunther A., Thede C. et al. Biophysical inhibition
of synthetic phosphilipidlung surfactant apoprotein admixtures by
plasma proteins. Chem. Phys. Lipids 1991; 57: 49—57. 
103. Gunther A., Kalinovski M., Rosseau S. et al. Surfactant incorporation
markedly alters mechanical properties of a fibrin clot. Am. J. Respir.
Cell Mol. Biol. 1995; 13: 712—718. 
104. Seeger W., Elssner A., Gunter A. et al. Lung surfactant phospholipids
associate with polymerizing fibrin: loss of surface activity. Am. J.
Respir. Cell Mol. Biol. 1993; 9: 213—220. 
105. Gunther A., Markart P., Kalinowski M. et al. Cleavage of surfactant
incorporated fibrin by different fibrinolytic agents. Kinetics of lysis
and rescue of surface activity. Am. J. Respir. Cell Mol. Biol. 1999; 21:
738—745. 
106. Schermuly R. T., Gunter A., Ermert M. et al. Conebulization of surfac
tant and urokinase restores gas exchange in perfused lungs with alve
olar fibrin formation. Am. J. Physiol. Lung Cell Mol. Physiol. 2001;
280: 792—800. 
107. Baker C. S., Evans T. W., Randle B. J. et al. Damage to surfactantspe
cific protein in acute respiratory distress syndrome. Lancet 1999; 353:
1232—1235. 
108. Pison U., Obertacke U., Brand M. et al. Altered pulmonary surfactant
in uncomplicated and septicemiacomplicated courses of acute respi
ratory failure. J. Trauma 1990; 30: 19—26. 
109. Petty T. L., Silvers G. W., Paul G. et al. Abnormalities in lung elastic
properties and surfactant function in adult respiratory distress syn
drome. Chest 1979; 75: 571—574. 
110. Günter A., Schmidt R., Harold J. at al. Bronchoscopic administration of
bovine natural surfactant in ARDS and septic shock: impact of bio
physical and biochemical surfactant properties. Eur. Respir. J. 2002;
19: 797—804. 
111. Gregory T. J., Steinberg K. R., Spragg R. et al. Bovine surfactant thera
py for patients with acute respiratory distress syndrome. Am. J. Resp.
Crit. Care Med. 1997; 155: 1309—1315. 
112. Hohlfeld J. M. Potential role of surfactant in asthma. Appl.
Cardiopulm. Pathophysiol. 2004; 13 (1): 44—45. 
113. Kurashima K., Fuimura M., Matsuda T., Kobauashi T. Surface activity
of sputum from acute asthmatic patients. Am. J. Respir. Crit. Care
Med. 1997; 155: 1254—1257. 
114. Cheng G. et al. Compositional and functional changes of pulmonary
surfactant in a guineapig model of chronic asthma. Respir. Med.
2001; 95: 180—186. 
115. Liu M., Wang L., Enhorning G. Surfactant dysfunction develops when
the immunized guineapig is challenged with ovalbumin aerosol. Clin.
Exp. Allergy 1995; 25: 1053—1056. 
116. Morley C. J. et al. Dry artificial lung surfactant and its effect on very
premature babies. Lancet 1981; 1: 64—66. 
117. Revak S. D., Merritt T. A., Hallman M. et al. The use of synthetic pep
tides in the formation of biophysically and biologically active pul
monary surfactants Pediatr. Res. 1991; 29: 460465. 
118. Häfner D., Germann P. =G., Hauschke D. Effects of rSPC surfactant
on oxygenation and histology in a ratlunglavage model of acute lung
injury. Am. J. Respir. Crit. Care Med. 1998; 158: 270—276. 
119. Баутин А. Е., Осовских В. В., Хубулава Г. Г. и др. Многоцентровые
клинические испытания сурфактантаBL для лечения респира
торного дистресссиндрома взрослых. Клинические исследова
ния лекарственных средств в России 2002; (2): 18—23. 
120. Curstedt T., Jornvall H., Berggren P. et al. Artificial surfactant based on
different hydrophobic lowmolecular — weight proteins. In: Lachmann
B. (ed.) Surfactant replacement therapy in neonatal and adult respira
tory distress syndrome. Berlin: SpringerVerlag; 1988. 332—337. 
121. Hallman M. , Meritt T. A., Schneider H. et al. Isolation of human sur
factant from amniotic fluid and pilot study of its efficacy in respirato
ry distress syndrome. Pediatrics 1983; 71: 473—482. 
О Б Щ А Я Р Е А Н И М А Т О Л О Г И Я , 2 0 0 7 , I I I ; 1
76

жүктеу/скачать 142,06 Kb.

Достарыңызбен бөлісу: